within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B05A_BloodAndRelatedProducts.B05AX03_BloodPlasma;

model BloodPlasma
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 0,
    adminDuration = 600,
    adminMass = 250 / 1000000,
    adminCount = 1,
    Vd = 5e-05,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>BloodPlasma</td></tr><tr><td>ATC code:</td><td>B05AX03</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>250</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.05</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0</td><td></td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Blood plasma is the liquid component of blood that serves as a medium for transporting nutrients, hormones, and waste products throughout the body. It is used therapeutically in plasma transfusions to treat patients with clotting disorders, trauma, burns, or in cases of massive blood loss. It is an approved and commonly used blood product in modern medicine.</p><h4>Pharmacokinetics</h4><p>Not applicable, as pharmacokinetic (PK) modeling in the classical sense (absorption, distribution, metabolism, excretion) is not standard for administered human plasma, which does not behave as a classical small molecule drug. Plasma is administered as a fluid replacement, and its behavior is governed by volume kinetics rather than traditional PK.</p><h4>References</h4><ol><li><p>Kim, P, et al., &amp; Garofolo, PM (2024). Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. <i>The Lancet. Infectious diseases</i> 24(12) 1319–1332. DOI:<a href=\"https://doi.org/10.1016/S1473-3099(24)00424-9\">10.1016/S1473-3099(24)00424-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39134085/\">https://pubmed.ncbi.nlm.nih.gov/39134085</a></p></li><li><p>Mairinger, S, et al., &amp; Kuntner, C (2020). Plasma pharmacokinetic and metabolism of [. <i>Nuclear medicine and biology</i> 84-85 28–32. DOI:<a href=\"https://doi.org/10.1016/j.nucmedbio.2020.01.001\">10.1016/j.nucmedbio.2020.01.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31981857/\">https://pubmed.ncbi.nlm.nih.gov/31981857</a></p></li><li><p>Abu Bakar, A, et al., &amp; Lyall, H (2025). Dosing, Toxicity and Drug Concentrations for Ganciclovir/Valganciclovir in Preterm and Low Birthweight Infants Treated for Cytomegalovirus. <i>The Pediatric infectious disease journal</i> 44(4) 319–325. DOI:<a href=\"https://doi.org/10.1097/INF.0000000000004605\">10.1097/INF.0000000000004605</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40063966/\">https://pubmed.ncbi.nlm.nih.gov/40063966</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B05AX03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end BloodPlasma;
